View source for CR:DOI:c8979d6d33702fc9854f30445fad20d0

{{#scite:
 |reference=guery2018ex
 |type=journal-article
 |title=Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial
 |author=Benoit Guery;Francesco Menichetti;Veli-Jukka Anttila;Nicholas Adomakoh;Jose Maria Aguado;Karen Bisnauthsing;Areti Georgopali;Simon D Goldenberg;Andreas Karas;Gbenga Kazeem;Chris Longshaw;Jose Alejandro Palacios-Fabrega;Oliver A Cornely;Maria J G T Vehreschild|+sep=;
 |journal=The Lancet Infectious Diseases
 |publisher=Elsevier BV
 |year=2018
 |volume=18
 |issue=3
 |pages=296-307
 |doi=10.1016/s1473-3099(17)30751-x
 |issn=1473-3099
 |retrieved-from=https://dx.doi.org/
 |retrieved-on=2026-04-08
 |@show=true
}}